What the Next Generation of Cancer Biomarkers May InvolveVideo Categories: 2018 ASCO Insights, Biomarkers, and Video Library
Dr Sanjiv Agarwala predicts that the cancer biomarkers of the future may be “mobile biomarkers,” meaning measures of the tumor microenvironment or immune response that change with therapy and may be able to determine treatment efficacy.
Ken Schaecher, MD, Medical Director of SelectHealth, describes in his opinion how there is no payer coverage issues with patients with polycythemia vera at this time. Supported through funding from Incyte
Dr Sibylle Loibl explains how fulvestrant (with or without palbociclib) fits in the treatment paradigm for patients with HR+/ HER2-negative metastatic breast cancer.